{"name":"Novaliq GmbH","slug":"novaliq-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Cyclosporine ophthalmic solution, 0.1%","genericName":"Cyclosporine ophthalmic solution, 0.1%","slug":"cyclosporine-ophthalmic-solution-0-1","indication":"Dry eye disease (keratoconjunctivitis sicca)","status":"marketed"},{"name":"Vehicle topical ocular, eye drops","genericName":"Vehicle topical ocular, eye drops","slug":"vehicle-topical-ocular-eye-drops","indication":"Treatment of dry eye disease","status":"phase_3"},{"name":"CyclASol Ophthalmic Solution","genericName":"CyclASol Ophthalmic Solution","slug":"cyclasol-ophthalmic-solution","indication":"Dry eye disease (keratoconjunctivitis sicca)","status":"phase_3"},{"name":"CyclASol topical ocular, eye drops","genericName":"CyclASol topical ocular, eye drops","slug":"cyclasol-topical-ocular-eye-drops","indication":"Dry eye disease (keratoconjunctivitis sicca)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Saline solution, 0.6%","genericName":"Saline solution, 0.6%","slug":"saline-solution-0-6","indication":"Corneal edema (Fuchs' endothelial dystrophy and other causes)","status":"marketed"}]}],"pipeline":[{"name":"Cyclosporine ophthalmic solution, 0.1%","genericName":"Cyclosporine ophthalmic solution, 0.1%","slug":"cyclosporine-ophthalmic-solution-0-1","phase":"marketed","mechanism":"Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation and reduces inflammatory cytokine production in the eye.","indications":["Dry eye disease (keratoconjunctivitis sicca)"],"catalyst":""},{"name":"Vehicle topical ocular, eye drops","genericName":"Vehicle topical ocular, eye drops","slug":"vehicle-topical-ocular-eye-drops","phase":"phase_3","mechanism":"Vehicle topical ocular eye drops act as a carrier for other medications, allowing them to be delivered directly to the eye.","indications":["Treatment of dry eye disease"],"catalyst":""},{"name":"CyclASol Ophthalmic Solution","genericName":"CyclASol Ophthalmic Solution","slug":"cyclasol-ophthalmic-solution","phase":"phase_3","mechanism":"CyclASol is a cyclosporine A ophthalmic emulsion that suppresses local immune responses in the eye to reduce inflammation and improve tear production in dry eye disease.","indications":["Dry eye disease (keratoconjunctivitis sicca)"],"catalyst":""},{"name":"CyclASol topical ocular, eye drops","genericName":"CyclASol topical ocular, eye drops","slug":"cyclasol-topical-ocular-eye-drops","phase":"phase_3","mechanism":"CyclASol is a cyclosporine A formulation in a novel aqueous nanomicellar vehicle designed to enhance corneal penetration and treat dry eye disease by suppressing ocular surface inflammation.","indications":["Dry eye disease (keratoconjunctivitis sicca)"],"catalyst":""},{"name":"Saline solution, 0.6%","genericName":"Saline solution, 0.6%","slug":"saline-solution-0-6","phase":"marketed","mechanism":"Hypotonic saline solution (0.6%) reduces corneal edema and improves corneal clarity by osmotically drawing fluid from swollen corneal tissue.","indications":["Corneal edema (Fuchs' endothelial dystrophy and other causes)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxNbVFSVXA0YVJHMlU3RHVhOE96eGtmUTVoU0t0Qmd3VHVMaXpHXzZRSjBCejlVd3MwQklsYWFteE9wWUEzTjJrZHVQZDhOTEctU0FEb1NNdTJzUzZ3R2Q2QWhuTElWSjFFTlRHenRobFd1cTZOT3JGZU9wdldNU0hsenN2TGliVGprUXZzTUxIWDl2QlJiRG9HYkVRSThWMDR2U3JWbE5WT2RrdTd5bDJKYUpiRnN2ZVU3ZXR1VTFzMnpDaHZJRU5NZnFpb29BbUYzR1ZxRUhOd2U3Z3d3eXAzcXdObTgxMXprc3RKRmptRjg3bjNDb0x1Q0toTWFkNlEzS2dmM25UN1hDS3YtazFtWnZrczgtMFI2ay1VQ0xFSDhJWEthdTl1VUpYZw?oc=5","date":"2025-07-08","type":"regulatory","source":"businesswire.com","summary":"Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD - businesswire.com","headline":"Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxPV29QQ2laTkliQVdxbmpDSUJPZ1IzcWVSbmRTX2RveVFIOGdMREhHbXR6aDVzczJMTlo3NnVHRm9mVzU2cEJQb0otSXNIVUtuVG1UOXE2ZFJkUnFKZWVHV1lQbDgzVHVYb01yMFpHcjNPVHFDaVV4UWg4SHR3YlhsNEczdldfX05vU1U4ajVVUlExeVpCdlRWNEJ3RGE3Tnp0cWwyaUZ1ZHhzTk1MTDU2V2pNV2hrbm9OSUN4QVhqZ1N6MW1TdWN4MzllLV8xTjVZS19tcU1sdExfekdMbFNMb3htMXlneHRuOElNWWtRVUtpbDg2SnR3RU1LazZjZw?oc=5","date":"2024-10-02","type":"regulatory","source":"businesswire.com","summary":"Novaliq and Laboratoires Théa Announce Partnership and EU Approval for Vevizye - businesswire.com","headline":"Novaliq and Laboratoires Théa Announce Partnership and EU Approval for Vevizye","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxQSWV4VUoxTzhYVTdwbWEyUjJBdUFBUTJWMEl0dTY1R1BZRzNJN242SDZNR0tDcEg5Snk1bjlMRmlqUXBJNDBpV2o0SmdDcTFkN0hWQlNOaFI5ZUw3N2RJVmJXOXE4VFV3U2hyTE1MYk01b2dyNU5HdFA4OXAtNnJIeF8yVjdiOUM2bW9BdU9zZTJ2bHVXR0hkNUQzejJlME9xRlpTRTgzWmxQRWxlaWYzZ2dnZzE3TDNteVFUcXlTZkFjQU1xSXVVby1WNDlZWnNxWkVmbmo1VnBTWWFaTnhwN0c5Q0c1X00xTXFjdS1qZmVjZzJCbFpDSkFwX2IyNTZFYllBeGNkS2M3OGNGLThYT2dFT1psU0tWTGZGaERESW1pRkZDTWt6Q1BveGFJVkwzeVdPdUh3cVd0Rlo5VmVJeQ?oc=5","date":"2023-06-13","type":"deal","source":"Via TT","summary":"Senju Pharmaceutical and Novaliq Enter Into License Agreement For NOV03 (Perfluorohexyloctane Ophthalmic Solution) For the Treatment of Dry Eye Disease in Japan - Via TT","headline":"Senju Pharmaceutical and Novaliq Enter Into License Agreement For NOV03 (Perfluorohexyloctane Ophthalmic Solution) For t","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxNYXliR2FuWTFmUFhmSVpBVFNvXzNVemg5WERYM2gyOWhEdE9PWC1KRlFZaGdjS1Z6dnhYYnJGU1hCWXJ0Tk1MWnEzS25INnVEZWRMM1JxOTVSSXR1dElUb1UzS0pibGlBR3l4aDNLM2hrS3dYdmVGbHRnYWttZUROMU5GT3JNNkluQy1xbV8zLXp0Y09jYlRoLUlUUHdFeWxnZjVmREFzM256OGxSMldEU2R0M3ViTUE4S3FEQjNRQjhZYWtlazc1U1BrTzFXbjN0eVdZWDdMd3JxWVR0V3paaG0zMDk4NE9HcUtPdlNfVy0yTnh6b2w1SGF4MUZHVC0xQVNDUzRnbGwxUmhEMGRYTWpRbENPRS1PTDVVMW1tVHNjRk9weVVaTlZqbFRobG8?oc=5","date":"2019-11-08","type":"deal","source":"newsfilecorp.com","summary":"Novaliq and Jiangsu Hengrui Medicine Announce a Strategic Collaboration in Ophthalmology for the EyeSol(R)-based, Investigational Products NOV03 and CyclASol(R) in China - newsfilecorp.com","headline":"Novaliq and Jiangsu Hengrui Medicine Announce a Strategic Collaboration in Ophthalmology for the EyeSol(R)-based, Invest","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNN3VGSlducGh1YjJ6VEdwX2N5WU01T01wMmVSTWZELTcwN0FIYjdpeTNnSm5YSFV3dHdyNFZhb0o2UDVENHQ3QUZNanpBcnhjUVEtMm5pQ3lILWFlMDVKT3poVGUtbnM0QVJJYUlhelFBTXdDaFIxZmptYkswQjRUd0YtQ2JMNkg5a2tlUklMZ2RVZXdVMFk2MVFMSjAzcUZQUDdyMlg5THJMeU9LVG51dnlidkh4QTRGaHpONkJMckU2MUE?oc=5","date":"2018-09-12","type":"pipeline","source":"BioSpace","summary":"In Australia, NovaTears® Eye Drops Are Available on the Pharmaceutical Benefits Scheme (PBS) from Now On - BioSpace","headline":"In Australia, NovaTears® Eye Drops Are Available on the Pharmaceutical Benefits Scheme (PBS) from Now On","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQU1k4WE5yaU5vUkhFUGZsVEhpSnlDOE1fQVcwdml6clh2Rk10Z1NtWm1wcWs3MzJTYmpMSU51TlpwbnVGbGpCMXBuQ1pHUkx1SjBoZlZGVmlHaGNjdUNlSGhVYTFZUWhFUm52Mlc4VUZ2R1J5RTZtMTVjZzNhZndNU3VRTTRaaV9mMzN0dENBZW0zakRnOUQ0RV9CdkVkZmNlczVGUHJiTDN0ZGFhWWY4?oc=5","date":"2017-03-21","type":"deal","source":"Drug Delivery Business","summary":"Novaliq, AFT Pharmaceuticals ink licensing deal for NovaTears dry eye therapy - Drug Delivery Business","headline":"Novaliq, AFT Pharmaceuticals ink licensing deal for NovaTears dry eye therapy","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"marketed":2,"phase_3":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}